SUGP2: A Drug Target / Disease Biomarker (G10147)

Target Name: SUGP2

NCBI ID: G10147

SUGP2

SUGP2: A Drug Target / Disease Biomarker

SUGP2, also known as supraglutide, is a drug that is currently being investigated as a potential treatment for type 2 diabetes. It is taken as an injection once a week and works by helping the body to produce more insulin and lower blood sugar levels.

One of the key benefits of SUGP2 is its ability to slow down the progression of type 2 diabetes. Studies have shown that people with type 2 diabetes who take SUGP2 have seen improvements in their blood sugar levels, as well as their overall health and quality of life.

Another potential benefit of SUGP2 is its potential to become a biomarker for the disease. A biomarker is a substance that is produced by the body that can be used as a sign of the presence of a particular disease or condition. Researchers are interested in using biomarkers to detect and monitor the progress of type 2 diabetes, as this could help to improve treatment outcomes.

In addition to its potential as a drug and biomarker, SUGP2 is also being studied for its potential benefits in other conditions. For example, some studies have shown thatSUGP2 may have anti-inflammatory effects, which could make it useful for treating a variety of inflammatory diseases.

Despite the potential benefits of SUGP2, it is still being studied in clinical trials to determine its safety and effectiveness. The most common side effects ofSUGP2 include nausea, vomiting, and diarrhea. In addition, some people may experience injection site reactions, such as redness, swelling, or itching.

Overall, SUGP2 is a drug that is still being investigated as a potential treatment for type 2 diabetes and may have a variety of potential benefits in addition to its use as a drug. As more research is conducted, it is likely that we will gain a better understanding of its potential and how it can be used to improve the lives of people with type 2 diabetes.

Protein Name: SURP And G-patch Domain Containing 2

Functions: May play a role in mRNA splicing

The "SUGP2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SUGP2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets